Children as young as 2 years may soon have access to the first-ever oral treatment for sudden hereditary angioedema (HAE) attacks. New Phase 3 data from developer Kalvista Pharmaceuticals suggests that Ekterly (sebetralstat) is both safe and effective for young children, offering a needle-free alternative to the…